FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

The FDA approved BridgeBio’s ​​acoramidis in a rare, genetic heart disease that’s expected to become an intense area of market competition, and a broad label will give it a near-immediate boost against the current leader ...